Bessemer Group’s Mereo BioPharma MREO Stock Holding History

Bessemer Group’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-58,000	Closed	-$41K	–	2314
2023 Q1	$41K	Hold	58,000	–	–	﹤0.01%	1260
2022 Q4	$44K	Hold	58,000	–	–	﹤0.01%	1170
2022 Q3	$50K	Hold	58,000	–	–	﹤0.01%	1162
2022 Q2	$65K	Hold	58,000	–	–	﹤0.01%	1079
2022 Q1	$65K	Hold	58,000	–	–	﹤0.01%	1032
2021 Q4	$93K	Hold	58,000	–	–	﹤0.01%	1012
2021 Q3	$140K	Hold	58,000	–	–	﹤0.01%	865
2021 Q2	$184K	Buy	+58,000	New	+$195K	﹤0.01%	809

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bessemer Group's MREO Position: Q2 2023 in Review

Bessemer Group sold out of Mereo BioPharma (MREO) in Q2 2023, closing a stake of 58,000 shares — an estimated $41K sold.

Bessemer Group first reported a position in MREO in Q2 2021 and held it in 8 quarters. The position peaked at $184K in Q2 2021. 53 funds tracked by Wall St. Rank hold MREO as of Q2 2023.

Bessemer Group reported no remaining Mereo BioPharma position as of Q2 2023 after selling out during the quarter.
Bessemer Group sold 58,000 Mereo BioPharma shares in Q2 2023, an estimated $41K.
Bessemer Group first reported a position in Mereo BioPharma in Q2 2021 and held it in 8 quarters.
Bessemer Group's Mereo BioPharma position peaked at $184K in Q2 2021.
53 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2023.

Based on Bessemer Group's 13F filing for Q2 2023, filed 10 Aug 2023.